These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38045287)

  • 1. Rifampicin tolerance and growth fitness among isoniazid-resistant clinical
    Vijay S; Bao NLH; Vinh DN; Nhat LTH; Thu DDA; Quang NL; Trieu LPT; Nhung HN; Ha VTN; Thai PVK; Ha DTM; Lan NH; Caws M; Thwaites GE; Javid B; Thuong NTT
    bioRxiv; 2024 May; ():. PubMed ID: 38045287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Most-Probable-Number-Based Minimum Duration of Killing Assay for Determining the Spectrum of Rifampicin Susceptibility in Clinical Mycobacterium tuberculosis Isolates.
    Vijay S; Nhung HN; Bao NLH; Thu DDA; Trieu LPT; Phu NH; Thwaites GE; Javid B; Thuong NTT
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and patterns of rifampicin and isoniazid resistance conferring mutations in Mycobacterium tuberculosis isolates from Uganda.
    Kigozi E; Kasule GW; Musisi K; Lukoye D; Kyobe S; Katabazi FA; Wampande EM; Joloba ML; Kateete DP
    PLoS One; 2018; 13(5):e0198091. PubMed ID: 29847567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
    Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
    PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
    Tahseen S; Khanzada FM; Rizvi AH; Qadir M; Ghazal A; Baloch AQ; Mustafa T
    PLoS One; 2020; 15(9):e0239328. PubMed ID: 32966321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan.
    Kozhamkulov U; Akhmetova A; Rakhimova S; Belova E; Alenova A; Bismilda V; Chingissova L; Ismailov S; Ramanculov E; Momynaliev K
    Jpn J Infect Dis; 2011; 64(3):253-5. PubMed ID: 21617314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
    Mushtaq F; Raza SM; Ahmad A; Aslam H; Adeel A; Saleem S; Ahmad I
    PLoS One; 2023; 18(10):e0293194. PubMed ID: 37883448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro bactericidal activity of 3-cinnamoyl-4-hydroxy-6-methyl-2-pyrone (CHP) against drug-susceptible, drug-resistant and drug-tolerant isolates of Mycobacterium tuberculosis.
    Bhat ZS; Rather MA; Ul Lah H; Hussain A; Maqbool M; Yousuf SK; Jabeen Z; Wani MA; Ahmad Z
    J Glob Antimicrob Resist; 2020 Sep; 22():57-62. PubMed ID: 31809940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the GenoType MTBDRplus assay for detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates in central Ethiopia.
    Bedewi Omer Z; Mekonnen Y; Worku A; Zewde A; Medhin G; Mohammed T; Pieper R; Ameni G
    Int J Mycobacteriol; 2016 Dec; 5(4):475-481. PubMed ID: 27931690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda.
    Traore H; Ogwang S; Mallard K; Joloba ML; Mumbowa F; Narayan K; Kayes S; Jones-Lopez EC; Smith PG; Ellner JJ; Mugerwa RD; Eisenach KD; McNerney R
    Ann Clin Microbiol Antimicrob; 2007 Jan; 6():1. PubMed ID: 17212825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand.
    Prommi A; Wongjarit K; Petsong S; Somsukpiroh U; Faksri K; Kawkitinarong K; Payungporn S; Rotcheewaphan S
    Microbiol Spectr; 2024 Mar; 12(3):e0346223. PubMed ID: 38323824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families.
    Kasule GW; Kateete DP; Joloba ML
    BMC Infect Dis; 2016 Apr; 16():173. PubMed ID: 27097724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
    Valvatne H; Syre H; Kross M; Stavrum R; Ti T; Phyu S; Grewal HM
    J Antimicrob Chemother; 2009 Oct; 64(4):694-701. PubMed ID: 19710078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazinamide resistance in rifampicin discordant tuberculosis.
    Mvelase NR; Singh R; Swe Swe-Han K; Mlisana KP
    PLoS One; 2022; 17(9):e0274688. PubMed ID: 36129921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Genome Sequencing for Resistance Level Prediction in Multidrug-Resistant Tuberculosis.
    Li J; Yang T; Hong C; Yang Z; Wu L; Gao Q; Yang H; Tan W
    Microbiol Spectr; 2022 Jun; 10(3):e0271421. PubMed ID: 35658579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypically occult multidrug-resistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment.
    Ho J; Jelfs P; Sintchencko V
    J Antimicrob Chemother; 2013 Dec; 68(12):2915-20. PubMed ID: 23838950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Tilahun M; Shimelis E; Wogayehu T; Assefa G; Wondimagegn G; Mekonnen A; Hailu T; Bobosha K; Aseffa A
    PLoS One; 2020; 15(8):e0236054. PubMed ID: 32750053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.